CRNDE

Summary

CRNDE (colorectal neoplasia differentially expressed, HGNC:37078) is a long non-coding RNA gene on chromosome 16q12.2.

This gene is transcribed into multiple transcript variants, some of which may function as non-coding RNAs. One of the transcript variants encodes a putative short protein that is localized to the nucleus (PMID:25978564). Expression of this locus is increased in proliferating tissues, including certain tumors such as colorectal adenomas and adenocarcinomas. Transcription from this gene is negatively regulated by insulin and insulin-like growth factors, and may regulate the expression of genes involved in metabolism.

Source: NCBI Gene 643911 — RefSeq curated summary.

At a glance

• Gene type: non-coding (lncRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:37078
Approved symbol	CRNDE
Name	colorectal neoplasia differentially expressed
Location	16q12.2
Locus type	RNA, long non-coding
Status	Approved
Aliases	LOC643911, LINC00180, CRNDEP
Ensembl gene	ENSG00000245694
Ensembl biotype	lncRNA
OMIM	615624
Entrez	643911
RNAcentral	URS0002123222 — lncRNA, 756 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 116 — 116 lncRNA

ENST00000501177, ENST00000502066, ENST00000557792, ENST00000558031, ENST00000558952, ENST00000559432, ENST00000559598, ENST00000560029, ENST00000560208, ENST00000560912, ENST00000561591, ENST00000613942, ENST00000635991, ENST00000637011, ENST00000654070, ENST00000655114, ENST00000657142, ENST00000658082, ENST00000659020, ENST00000660344, ENST00000661312, ENST00000661493, ENST00000667913, ENST00000668556, ENST00000686100, ENST00000688921, ENST00000689375, ENST00000689582, ENST00000691307, ENST00000701575, ENST00000701876, ENST00000717492, ENST00000717493, ENST00000750651, ENST00000750652, ENST00000750653, ENST00000750654, ENST00000750655, ENST00000750656, ENST00000750657, ENST00000750658, ENST00000750659, ENST00000750660, ENST00000750661, ENST00000750662, ENST00000750663, ENST00000750664, ENST00000750665, ENST00000750666, ENST00000750667, ENST00000750668, ENST00000750669, ENST00000750670, ENST00000750671, ENST00000750672, ENST00000750673, ENST00000750674, ENST00000750675, ENST00000750676, ENST00000750677, ENST00000750678, ENST00000750679, ENST00000750680, ENST00000750681, ENST00000750682, ENST00000750683, ENST00000750684, ENST00000750685, ENST00000750686, ENST00000750687, ENST00000750688, ENST00000750689, ENST00000750690, ENST00000750691, ENST00000750692, ENST00000750693, ENST00000750694, ENST00000750695, ENST00000750696, ENST00000750697, ENST00000750698, ENST00000750699, ENST00000750700, ENST00000750701, ENST00000750702, ENST00000750703, ENST00000750704, ENST00000750705, ENST00000750706, ENST00000750707, ENST00000750708, ENST00000750709, ENST00000750710, ENST00000750711, ENST00000750712, ENST00000750713, ENST00000750714, ENST00000750715, ENST00000750716, ENST00000750717, ENST00000750718, ENST00000750719, ENST00000750720, ENST00000750721, ENST00000750722, ENST00000750723, ENST00000750724, ENST00000750725, ENST00000750726, ENST00000750727, ENST00000750728, ENST00000750729, ENST00000750730, ENST00000750731, ENST00000750732, ENST00000750733

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000501177 — 5 exons

Exon	Start	End
ENSE00001975513	54925101	54925213
ENSE00002554798	54923585	54923650
ENSE00002570530	54920298	54920338
ENSE00004095192	54918216	54919209
ENSE00004095298	54928494	54928716

Expression profiles

Bgee: expression breadth ubiquitous, 243 present calls, max score 99.93.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 19.9223 / max 242.2326, expressed in 1614 samples.

FANTOM5 promoters (10 alternative TSS)

Promoter ID	TPM avg	Samples expressed
157428	14.3069	1555
157431	3.6420	1134
157425	0.6324	356
157429	0.4731	300
157430	0.3403	206
157424	0.2859	79
157427	0.2055	91
157423	0.0188	3
157426	0.0105	4
157422	0.0067	3

Top tissues by expression

250 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sperm	CL:0000019	99.93	gold quality
bronchial epithelial cell	CL:0002328	99.32	gold quality
right testis	UBERON:0004534	99.16	gold quality
bronchus	UBERON:0002185	99.08	gold quality
left testis	UBERON:0004533	99.08	gold quality
germinal epithelium of ovary	UBERON:0001304	99.04	gold quality
adult organism	UBERON:0007023	98.96	gold quality
tibia	UBERON:0000979	98.76	gold quality
parotid gland	UBERON:0001831	98.34	gold quality
epithelium of nasopharynx	UBERON:0001951	98.04	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	97.77	gold quality
palpebral conjunctiva	UBERON:0001812	97.63	gold quality
mucosa of paranasal sinus	UBERON:0005030	97.48	gold quality
upper arm skin	UBERON:0004263	97.34	gold quality
oviduct epithelium	UBERON:0004804	97.30	gold quality
testis	UBERON:0000473	97.23	gold quality
upper leg skin	UBERON:0004262	96.82	gold quality
nasal cavity mucosa	UBERON:0001826	96.63	gold quality
esophagus squamous epithelium	UBERON:0006920	96.45	gold quality
epithelium of mammary gland	UBERON:0003244	96.38	gold quality
skin of hip	UBERON:0001554	96.36	gold quality
mammary duct	UBERON:0001765	96.35	gold quality
penis	UBERON:0000989	95.71	gold quality
mammary gland	UBERON:0001911	95.64	gold quality
thoracic mammary gland	UBERON:0005200	95.59	gold quality
mammalian vulva	UBERON:0000997	95.49	gold quality
trachea	UBERON:0003126	94.84	gold quality
saliva-secreting gland	UBERON:0001044	94.52	gold quality
right uterine tube	UBERON:0001302	94.42	gold quality
tibialis anterior	UBERON:0001385	94.16	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	22.05

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• In colorectal cancer cells, nuclear CRNDE transcripts are downregulated by the MAPK and PI3K arms of the insulin/IGF signaling pathway. These transcripts are implicated in the control of glucose and lipid metabolism, and may mediate some of insulin’s effects. In particular, they seem to promote aerobic glycolysis (Warburg effect). (PMID:24184209)
• This is the first report of a long non-coding RNA regulated by insulin/IGFs. (PMID:24184209)
• CRNDE, a long-noncoding RNA, promotes glioma cell growth and invasion through mTOR signaling pathway. (PMID:25813405)
• CRNDE played an oncogenic role of glioma stem cells through the negative regulation of miR-186. (PMID:26231038)
• Our results depict CRNDE as a potential marker of poor prognosis in women with ovarian carcinomas (PMID:26556866)
• we conclude that DMBT1 by binding with CRNDE and c-IAP1 associated with PI3K-AKT pathway is crucial for GBC carcinogenesis, and targeting this pathway may be pivotal in the treatment of GBC. (PMID:27637083)
• Study shows that CRNDE lncRNA is hypermethylated in chronic lymphocytic leukemia (CLL) and identifies CRNDE with a potential role in CLL disease pathogenesis and/or prognosis. (PMID:27777635)
• Up-regulation of exosomal long noncoding RNA CRNDE-h is a novel serum-based biomarker for diagnosis and prognosis of colorectal cancer. (PMID:27888803)
• the lncRNA CRNDE could regulate the progression and chemoresistance of CRC via modulating the expression levels of miR-181a-5p and the activity of Wnt/beta-catenin signaling. (PMID:28086904)
• CRNDE is significantly up-regulated in hepatoblastoma samples and metastatic hepatoblastoma cell lines. CRNDE up-regulation contributes to tumor growth and hypervascularity of hepatoblastoma via mTOR signaling activation. (PMID:28178668)
• CRNDE down-regulation inhibited the cell proliferation, migration and invasion in vitro and in vivo and the inhibitions were both completely blocked after miR-217 inhibition or TCF7L2 overexpression. (PMID:28472810)
• CRNDE strongly promoted NSCLC cell proliferation and growth through activating PI3K/AKT signalling (PMID:28477368)
• The lncRNA CRNDE promoted gastric cancer cell proliferation by competitively binding miR-145, and described a novel CRNDE/miR-145/E2F3 signaling pathway with a regulatory function in gastric cancer. (PMID:28490034)
• Data suggest that CRNDE may function as an oncogene by modulating p21, finally contributing to the radioresistant phenotype formation of LAD cells. (PMID:28550688)
• it was demonstrated that CRNDE could form a functional complex with heterogeneous nuclear ribonucleoprotein U-like 2 protein (hnRNPUL2) and direct the transport of hnRNPUL2 between the nucleus and cytoplasm. (PMID:28594403)
• We found that over-expression of CRNDE in astrocytes increased the expression of key factors in the toll-like receptor signaling pathway, especially toll-like receptor-3-mediated MyD88-independent pathway.We speculated that CRNDE might trigger inflammation to regulate tumorigenesis and tumor development through the toll-like receptor pathway (PMID:28621230)
• LncRNA CRNDE could promote the cell growth and stimulate the metastasis of cervical cancer cells (PMID:29194035)
• Results indicated that CRNDE functioned as an oncogene in osteosarcoma cell lines, and CRNDE may exert its oncogenic role via regulating Notch1 signaling and EMT in osteosarcoma. (PMID:29246789)
• CRNDE promotes cancer cell proliferation, migration and invasion, and suppresses apoptosis in complicated mechanisms, which result in the initialization and development of human cancers. [review] (PMID:29405523)
• LncRNA-CRNDE is highly expressed in the bone marrow tissues of acute myeloid leukemia patients and is negatively correlated with survival. (PMID:29461608)
• We have presented evidence that CRNDE was significantly increased in bladder cancer, and overexpressed expression of CRNDE was positively related with advanced TNM stage of bladder cancer patients (PMID:29710461)
• Experimental profiles of 12 alternatively spliced isoforms demonstrated that the spliced variant CRNDE-g was the most highly expressed isoform in multiple cancer types. Collectively, the results emphasize the cancer-associated feature of CRNDE and its spliced isoforms, and may provide promising targets for cancer diagnosis and therapy. (PMID:29808251)
• CRNDE promotes Hepatocellular carcinoma cell proliferation and growth in vitro and in vivo. (PMID:29864897)
• CRNDE overexpression accelerated lipopolysaccharide-induced apoptosis and inflammation via up-regulation of FOXM1 in WI-38 cells. (PMID:29864958)
• levels of CRNDE were negatively correlated with overall survival of patients with clear cell renal cell carcinoma (ccRCC), and high-expression of CRNDE was an independent poor prognostic factor for patients with ccRCC. (PMID:30129055)
• Long non-coding RNA CRNDE promotes the proliferation, migration and invasion of hepatocellular cacinoma cells through miR-217/MAPK1 axis. (PMID:30246921)
• CRNDE knockdown and CCL18 promoted melanoma cell apoptosis and G0/G1 cell cycle arrest, as well as inhibited the melanoma cell growth in vitro and in vivo. CRNDE promotes the migration and invasion of melanoma by sponging miR-205 and releasing CCL18. (PMID:30257602)
• CRNDE may be involved in the development and progression of postmenopausal osteoporosis. (PMID:30280760)
• CRNDE influences proliferation and apoptosis in cervical cancer cells; the PI3K/AKT pathway was inactivated in response to CRNDE knockdown (PMID:30334449)
• The overexpression of CRNDE promoted tumor cell proliferation, migration, and invasion, upregulated miR- 136-5P could largely reverse these effects. CRNDE upregulated the expression of IRX5 to promote tumor development by binding miR-136-5P. (PMID:30423553)
• CRNDE could be a potential biomarker for cancer diagnosis and prognosis. (PMID:30463803)
• CRNDE was confirmed an oncogene, and its up-regulated expression significantly correlated with poor prognosis and advanced colorectal tumor progression. [review] (PMID:30509091)
• Crnde expression is negatively correlated with that of cardiac fibrosis marker genes and is enriched in cardiac fibroblasts. (PMID:30748104)
• CRNDE level was upregulated in NSCLC, and its knockdown suppressed NSCLC cells proliferation and enhanced apoptosis, whereas miR-641 antagonized the regulatory effect of CRNDE knockdown by directly binding to CRNDE. (PMID:30982057)
• LncRNA CRNDE promotes hepatocellular carcinoma progression by upregulating SIX1 through modulating miR-337-3p. (PMID:31099050)
• CRNDE bond to p53 upregulated modulator of apoptosis (PUMA), and PUMA was required for CRNDE to enhance cervical cancer cell growth. (PMID:31202167)
• CRNDE promoted dextran sulfate sodium-induced colonic epithelial cell apoptosis via suppressing miR-495. (PMID:31251902)
• Bioinformatics analysis identified four hub lncRNAs involved in the process of drug resistance in the chemotherapy of colorectal cancer (CRC), including CRNDE, H19, UCA1 and HOTAIR, which are predictive factors for treatment sensitivity. Among them, HOTAIR stands out as a strong factor, the elevated expression of which is also associated with advanced tumor node and metastasis stage and poor CRC disease prognosis. (PMID:31432188)
• Linkage of lncRNA CRNDE sponging miR-181a-5p with aggravated inflammation underlying sepsis. (PMID:31604377)
• LncRNA CRNDE acts as an oncogene in cervical cancer through sponging miR-183 to regulate CCNB1 expression. (PMID:31605132)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.